Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013

Area of Science:

• Neurology
• Pharmacology
• Epidemiology

Background:

• Previous research indicated a potential link between statin use and polyneuropathy risk, but findings were inconsistent.
• This study aimed to re-evaluate this association using a larger dataset and a similar methodology to prior work.

Purpose of the Study:

• To confirm or refute the association between statin use and the risk of developing idiopathic polyneuropathy.
• To investigate different patterns of statin use, including duration and intensity, in relation to polyneuropathy risk.

Main Methods:

• A case-control study design was employed, identifying 370 validated cases of idiopathic polyneuropathy and 7400 matched controls from medical registry data (1999-2013).
• Statin exposure (ever use, current use, past use, long-term use, high-intensity use) was determined via prescription registry data.
• Conditional logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between statin use and polyneuropathy.

Main Results:

• No statistically significant association was found between ever using statins and the risk of idiopathic polyneuropathy (OR 1.14, 95% CI 0.84, 1.54).
• Specific patterns of statin use, including current use, long-term use, and high-intensity use, also showed no significant association with increased polyneuropathy risk.
• The results indicate that various statin exposure levels do not elevate the likelihood of developing idiopathic polyneuropathy.

Conclusions:

• Statin use, regardless of duration or intensity, is not associated with an increased risk of idiopathic polyneuropathy.
• The findings do not support a causal link between statins and the development of this neurological condition.
• This study provides robust evidence that statins can be safely used without concern for inducing idiopathic polyneuropathy.